BCM
SCLN

Bayesian Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Bayesian Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-12,100
Closed -$111K – 482
2015
Q4 		$111K Buy
+12,100
New +$101K 0.16% 211

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayesian Capital Management's SCLN Position: Q1 2016 in Review

Bayesian Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2016, closing a stake of 12,100 shares — an estimated $111K sold.

Bayesian Capital Management first reported a position in SCLN in Q4 2015 and held it in 1 quarter. The position peaked at $111K in Q4 2015. 142 funds tracked by Wall St. Rank hold SCLN as of Q1 2016.

  • Bayesian Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • Bayesian Capital Management sold 12,100 Sciclone Pharmaceuticals Inc shares in Q1 2016, an estimated $111K.
  • Bayesian Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q4 2015 and held it in 1 quarter.
  • Bayesian Capital Management's Sciclone Pharmaceuticals Inc position peaked at $111K in Q4 2015.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2016.

Based on Bayesian Capital Management's 13F filing for Q1 2016, filed 16 May 2016.